Therapeutic Asset Ratings
329 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Efineptakin Alfa
Plasma Cell Myeloma
Washington University School of Medicine
P1
C
(36)
Egfrt/Bcma-41Bbz Car T Cell
Plasma Cell Myeloma
Memorial Sloan Kettering Cancer Center
P1
C
(36)
Fhnd6091
Plasma Cell Myeloma
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
P1
C
(36)
Fianlimab
Plasma Cell Myeloma
Regeneron Pharmaceuticals
P1
C
(36)
Icovamenib
Plasma Cell Myeloma
Biomea Fusion Inc.
P1
C
(36)
IDETREXED
Multiple Myeloma
Medical College of Wisconsin
P1
C
(36)
Igm-2644
Plasma Cell Myeloma
IGM Biosciences, Inc.
P1
C
(36)
Immunoglobulin G1 [de-451-lysine], anti-(human/Macaca fascicularis/Macaca mulatta/Chlorocebus sabaeus MHC class I chain-related protein MICA/MHC class I chain-related protein MICB) (human-Mus musculus monoclonal CLN-619 ?1-chain), disulfide with human-Mus musculus monoclonal CLN-619 [34-leucine] ?-chain, dimer
Plasma Cell Myeloma
Cullinan Therapeutics Inc.
P1
C
(36)
Ingitamig
Plasma Cell Myeloma
Celgene
P1
C
(36)
Ksvcbd
Plasma Cell Myeloma
Chinese PLA General Hospital
P1
C
(36)
KTX-1001
Plasma Cell Myeloma
K36 Therapeutics, Inc.
P1
C
(36)
Loxo-338
Plasma Cell Myeloma
Eli Lilly and Company
P1
C
(36)
lp-118
Plasma Cell Myeloma
Newave Pharmaceutical Inc
P1
C
(36)
Mcarh109
Plasma Cell Myeloma
Memorial Sloan Kettering Cancer Center
P1
C
(36)
Mcarh125
Plasma Cell Myeloma
Memorial Sloan Kettering Cancer Center
P1
C
(36)
Nms-03597812
Plasma Cell Myeloma
Nerviano Medical Sciences
P1
C
(36)
OL-101
Plasma Cell Myeloma
Zhejiang University
P1
C
(36)
OriC321
Plasma Cell Myeloma
Zhejiang University
P1
C
(36)
P-Bcma-Allo1 Car-T Cells
Plasma Cell Myeloma
Poseida Therapeutics, Inc.
P1
C
(36)
Pirtobrutinib
Plasma Cell Myeloma
Eli Lilly and Company
P1
C
(36)
RECOMBINANT FULLY HUMAN IGG1 KAPPA ANTI-TIGIT MONOCLONAL ANTIBODY EOS-448
Plasma Cell Myeloma
iTeos Therapeutics
P1
C
(36)
Recombinant Glycosylated Human Interleukin-7
Plasma Cell Myeloma
Washington University School of Medicine
P1
C
(36)
Romosozumab
Plasma Cell Myeloma
Memorial Sloan Kettering Cancer Center
P1
C
(36)
Shr-3836 Administered As Multiple Doses.
Plasma Cell Myeloma
Shanghai Hengrui Pharmaceutical Co., Ltd.
P1
C
(36)
Shr-9539 For
Plasma Cell Myeloma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
P1
C
(36)
Showing 251 to 275 of 329 assets
Previous
Page 11 of 14
Next
